34961-64-3

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-FORMYLPHENYL)PROPANOIC ACID is used as an intermediate in the manufacture of pharmaceuticals for its ability to be further modified and incorporated into the synthesis of various drug molecules. Its unique structure allows for the development of new therapeutic agents with potential applications in treating a range of medical conditions.

InChI:InChI=1/C10H10O3/c11-7-9-3-1-8(2-4-9)5-6-10(12)13/h1-4,7H,5-6H2,(H,12,13)

Upstream product

• 23359-08-2 4-formylcinnamic acid 
• 3984-22-3 2-vinyl-1,3-dioxolane 
• 1122-91-4 4-bromo-benzaldehyde 
• 38628-53-4 3-<4-(hydroxymethyl)phenyl>propanol 
• 623-27-8 terephthalaldehyde, 
• 619-66-9 4-Carboxybenzaldehyde 
• 141286-90-0 methyl (E)-3-(4-(hydroxymethyl)phenyl)acrylate 
• 115974-97-5 methyl (E)-4-carboxyl cinnamate 
• 105-07-7 4-cyanobenzaldehyde 
• 42287-94-5 (4-cyanophenyl)propionic acid 
• 90392-95-3 3-(4'-formylphenyl)propanal 
• 87199-17-5 4-formylphenylboronic acid, 
• 79-10-7 acrylic acid 
• 56703-34-5 3-[4-(hydroxymethyl)phenyl]propanoic acid 

Downstream Products

• 3179-13-3 3-[4-((E)-2-Nitro-vinyl)-phenyl]-propionic acid 
• 1018674-56-0 3-[4-({4-[(benzyloxy)carbonyl]-3-[(cyclopentyloxy)carbonyl]piperazin-1-yl}methyl)phenyl]propanoic acid 
• 60795-00-8 2-hydroxy-2-phenyl-4-[4-(2-carboxyethyl)phenyl]-3(2H)-furanone 
• 1018674-58-2 cyclopentyl 4-(4-{3-[(1-isobutoxyethoxy)amino]-3-oxopropyl}benzyl)piperazine-2-carboxylate 
• 1018674-57-1 1-benzyl 2-cyclopentyl 4-(4-{3-[(1-isobutoxyethoxy)amino]-3-oxopropyl}benzyl)piperazine-1,2-dicarboxylate 
• 1622313-43-2 4-(3-oxo-3-(3,4,4-trimethyl-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)propyl)benzaldehyde 

Relevant academic research and scientific papers

The polymorphism of porphyrin 2D assemblies at the liquid-graphite interface: The effect of a polar solvent additive and a flexible spacer on the face-on and edge-on type molecular arrangements

Self-assembly structures of 5,10,15,20-tetrakis(4-substituted phenyl)porphyrins at the liquid-graphite interface were investigated by scanning tunneling microscopy. We found that the presence of a small amount of a polar solvent, i.e., only 0.5 vol% of octanoic acid in phenyloctane, significantly affected the selective formation of the face-on polymorph over the edge-on one likely due to the solvent-molecule interactions at the 2D interface.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

Selective oxoammonium salt oxidations of alcohols to aldehydes and aldehydes to carboxylic acids

The oxidation of alcohols to aldehydes using stoichiometric 4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxoammonium tetrafluoroborate (1) in CH2Cl2 at room temperature is a highly selective process favoring reaction at the carbinol center best able to accommodate a positive charge. The oxidation of aldehydes to carboxylic acids by 1 in wet acetonitrile is also selective; the rate of the process correlates with the concentration of aldehyde hydrate. A convenient and high yield method for oxidation of alcohols directly to carboxylic acids has been developed.

Chemoselective conversion of α-unbranched aldehydes to amides, esters, and carboxylic acids by NHC-catalysis

Depending on the N-heterocyclic carbene catalyst utilized, α-unbranched aldehydes selectively provided amides, esters, or carboxylic acids through oxidation by NCS. The α-unbranched aldehyde underwent these reactions chemoselectively in the presence of an aromatic or α-branched aldehyde.

NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS

The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

Rhodium(I)-catalyzed 1,4-addition of arylboronic acids to acrylic acid in water: One-step preparation of 3-arylpropionic acids

A practical method for the one-step preparation of 3-arylpropionic acids through rhodium-catalyzed 1,4-addition of arylboronic acids to acrylic acid is reported. The method is applicable to a broad scope of aryl boronic acids and displays a wide functional group tolerance operating in water as the optimal reaction medium. Georg Thieme Verlag Stuttgart · New York.

N-Hydroxy-(4-oxime)-cinnamide: A versatile scaffold for the synthesis of novel histone deacetilase (HDAC) inhibitors

With the aim to discover novel HDAC inhibitors with high potency and good safety profiles, we have designed a small library based on a N-hydroxy-(4-oxime)-cinnamide scaffold. We describe the synthesis of these novel compounds and some preliminary in vitro

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.

Cinnamic, Phenylpropiolic and Phenylpropanoic Acid Derivatives Useful as Anti-Tumor Agents

Cinnamic and phenylpropiolic acid derivatives of formula (I) having antitumour and chemo sensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumours.

Novel Thiophene Derivatives as Spingosine-1-Phosphate-1 Receptor Agonists

The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.